1.
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
by Fayad, Zahi A, Prof
The Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559

2.
Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)
by Woodward, Mark
Heart (British Cardiac Society), 2007-02, Vol.93 (2), p.172-176

3.
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
by Muntner, Paul, PhD
The American heart journal, 2011, Vol.161 (4), p.719-725

4.
Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fl...
by Fayad, Zahi A., PhD
The American heart journal, 2011, Vol.162 (2), p.214-221.e2

5.
Combined Role of Reduced Estimated Glomerular Filtration Rate and Microalbuminuria on the Prevalence of Peripheral Arterial Disease
by Baber, Usman, MD
The American journal of cardiology, 2009, Vol.104 (10), p.1446-1451

6.
Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease:...
by Chalmers, John
Hypertension (Dallas, Tex. 1979), 2014-02, Vol.63 (2), p.259-264

7.
Effects of Prehypertension and Hypertension Subtype on Cardiovascular Disease in the Asia-Pacific Region
by Arima, Hisatomi
Hypertension (Dallas, Tex. 1979), 2012-06, Vol.59 (6), p.1118-1123

8.
Impact of Blood Pressure Lowering on Cardiovascular Outcomes in Normal Weight, Overweight, and Obese Individuals: The Perindopril Protection Against Recurrent Stroke Study Trial
by Czernichow, Sébastien
Hypertension (Dallas, Tex. 1979), 2010-05, Vol.55 (5), p.1193-1198
